Abstract
Cancer is considered as one of the world's leading causes of morbidity and mortality. Over the past four decades, spectacular advances in molecular and cellular biology have led to major breakthroughs in the field of cancer research. However, the design and development of anticancer drugs prove to be an intricate, expensive, and time-consuming process. To overcome these limitations and manage large amounts of emerging data, computer- aided drug discovery/design (CADD) methods have been developed. Computational methods can be employed to help and design experiments, and more importantly, elucidate structure-activity relationships to drive drug discovery and lead optimization methods. Structure- and ligand-based drug designs are the most popular methods utilized in CADD. Additionally, the assimilation provided by these two complementary approaches are even more intriguing. Nowadays, the integration of experimental and computational approaches holds great promise in the rapid discovery of novel anticancer therapeutics. In this review, we aim to provide a comprehensive view on the state-of-the-art technologies for computer-assisted anticancer drug development with thriving models from literature. The limitations associated with each traditional in silico method have also been discussed, which can help the reader to rationale the best computational tool for their analysis. In addition, we will also shed some light on the latest advances in the computational approaches for anticancer drug development and conclude with a brief precis.
Keywords: Cancer, anticancer, drug, structure-based, ligand-based, integration, pharmacophore, drug repositioning, polypharmacology.
Current Medicinal Chemistry
Title:Expediting the Design, Discovery and Development of Anticancer Drugs using Computational Approaches
Volume: 24 Issue: 42
Author(s): Shaherin Basith, Minghua Cui, Stephani J.Y. Macalino and Sun Choi*
Affiliation:
- National Leading Research Laboratory of Molecular Modeling & Drug Design (NLRL), College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760,Korea
Keywords: Cancer, anticancer, drug, structure-based, ligand-based, integration, pharmacophore, drug repositioning, polypharmacology.
Abstract: Cancer is considered as one of the world's leading causes of morbidity and mortality. Over the past four decades, spectacular advances in molecular and cellular biology have led to major breakthroughs in the field of cancer research. However, the design and development of anticancer drugs prove to be an intricate, expensive, and time-consuming process. To overcome these limitations and manage large amounts of emerging data, computer- aided drug discovery/design (CADD) methods have been developed. Computational methods can be employed to help and design experiments, and more importantly, elucidate structure-activity relationships to drive drug discovery and lead optimization methods. Structure- and ligand-based drug designs are the most popular methods utilized in CADD. Additionally, the assimilation provided by these two complementary approaches are even more intriguing. Nowadays, the integration of experimental and computational approaches holds great promise in the rapid discovery of novel anticancer therapeutics. In this review, we aim to provide a comprehensive view on the state-of-the-art technologies for computer-assisted anticancer drug development with thriving models from literature. The limitations associated with each traditional in silico method have also been discussed, which can help the reader to rationale the best computational tool for their analysis. In addition, we will also shed some light on the latest advances in the computational approaches for anticancer drug development and conclude with a brief precis.
Export Options
About this article
Cite this article as:
Basith Shaherin, Cui Minghua, Macalino J.Y. Stephani and Choi Sun*, Expediting the Design, Discovery and Development of Anticancer Drugs using Computational Approaches, Current Medicinal Chemistry 2017; 24 (42) . https://dx.doi.org/10.2174/0929867323666160902160535
DOI https://dx.doi.org/10.2174/0929867323666160902160535 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the Treatment of Chronic Inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protein Degradation by the Ubiquitin-Proteasome Pathway and Organ Fibrosis
Current Medicinal Chemistry Fighting Carcinogenesis with Plant Metabolites by Weakening Proliferative Signaling and Disabling Replicative Immortality Networks of Rapidly Dividing and Invading Cancerous Cells
Current Drug Delivery Pitfalls and Solutions for the Validation of Novel Drugs in Animal Models of Disease
Current Immunology Reviews (Discontinued) The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs
Current Cancer Drug Targets Perspectives of Plant Natural Products in Inhibition of Cancer Invasion and Metastasis by Regulating Multiple Signaling Pathways
Current Medicinal Chemistry Facile Synthesis of Stereoisomers of the Non-Secosteroidal Ligand LG190178 and their Evaluation Using the Mutant Vitamin D Receptor
Letters in Organic Chemistry Glycoprotein Targeting and Other Applications of Lectins in Biotechnology
Current Protein & Peptide Science Double Strand Break Repair Activities of p53 as Potential Tumor Suppressor Function Counteracting Mammary Tumor Development
Current Women`s Health Reviews The Autism Candidate Gene Neurobeachin Encodes a Scaffolding Protein Implicated in Membrane Trafficking and Signaling
Current Molecular Medicine Simple C-2-Substituted Quinolines and their Anticancer Activity
Letters in Drug Design & Discovery Mechlorethamine based Drug Structures for Intervention of Central Nervous System Tumors
Central Nervous System Agents in Medicinal Chemistry Antibody Recognition of Fluorinated Haptens and Antigens
Current Topics in Medicinal Chemistry Aldo-Keto Reductase Family 1 Member B1 Inhibitors: Old Drugs with New Perspectives
Recent Patents on Anti-Cancer Drug Discovery Regulation of Breast Cancer Progression by Noncoding RNAs
Current Cancer Drug Targets Flavopiridol, the First Cyclin-Dependent Kinase Inhibitor: Recent Advances in Combination Chemotherapy
Mini-Reviews in Medicinal Chemistry Editorial [Hot topic: Innate Immunity Molecules S100A8/A9 Involved in Stress Response and Cancer Biology (Guest Editors: Claus Kerkhoff and Saeid Ghavami)]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Activation of Intrinsic Apoptosis and G1 Cell Cycle Arrest by a Triazole Precursor, N-(4-chlorophenyl)-2-(4-(3,4,5-trimethoxybenzyloxy)benzoyl)-hydrazinecarbothioamide in Breast Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry A Dual Role of Cyclin E in Cell Proliferation and Apotosis May Provide a Target for Cancer Therapy
Current Cancer Drug Targets Vascular Effects of Phytoestrogens and Alternative Menopausal Hormone Therapy in Cardiovascular Disease
Mini-Reviews in Medicinal Chemistry ANN Classification and Modified Otsu Labeling on Retinal Blood Vessels
Current Signal Transduction Therapy